소화기 내시경 기기 시장 : 제품 유형별, 폼팩터별, 카테고리별, 적응증별, 용도별, 최종 사용자별, 연령층별, 판매 채널별 시장 예측(2026-2032년)

The Gastrointestinal Endoscopy Devices Market is projected to grow by USD 18.55 billion at a CAGR of 5.43% by 2032.

Gastrointestinal Endoscopy Devices Market Overview

The gastrointestinal endoscopy devices market is anchored by essential diagnostic and therapeutic demand across colorectal cancer screening, gastrointestinal bleeding management, inflammatory bowel disease surveillance, biliary intervention, and minimally invasive treatment of digestive disorders. Flexible endoscopes, endoscopic ultrasound systems, capsule endoscopy, visualization platforms, insufflators, reprocessing systems, hemostasis tools, biopsy forceps, snares, stents, and energy-based accessories form an increasingly integrated ecosystem.

Demand is supported by well-documented clinical need. The International Agency for Research on Cancer reported approximately 1.9 million new colorectal cancer cases worldwide in 2022, and the U.S. Preventive Services Task Force recommends colorectal cancer screening for adults aged 45 to 75. Evidence-based screening pathways continue to elevate procedure volumes, while hospitals and ambulatory endoscopy centers prioritize image quality, infection prevention, workflow efficiency, traceability, and AI-enabled lesion detection.

Transformative Shifts in the GI Endoscopy Landscape

The landscape is shifting from conventional diagnostic endoscopy toward digitally connected, therapy-capable, and workflow-optimized platforms. High-definition imaging, narrow-band and contrast-enhanced visualization, single-use duodenoscopes, advanced endoscopic ultrasound, capsule endoscopy, and endoscopic submucosal dissection tools are expanding the role of endoscopy beyond diagnosis into organ-sparing intervention.

Operationally, providers are redesigning endoscopy suites around throughput, safety, and traceability. Heightened reprocessing scrutiny, device-related infection prevention guidance, and the need to reduce repeat procedures are influencing procurement. Vendors that combine clinical performance with service models, physician training, software upgrades, cybersecurity readiness, and regulatory compliance are better positioned as capital budgets become more selective.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the gastrointestinal endoscopy devices value chain. Real-time computer-aided detection for colorectal polyps, quality metrics for withdrawal time and bowel preparation, automated documentation, lesion characterization, and training support are moving AI from pilot adoption to routine clinical workflow in leading centers.

The impact is not limited to diagnostic yield. AI can support capacity planning, procedure standardization, documentation consistency, and earlier escalation to therapeutic intervention when integrated with imaging systems and electronic health records. However, adoption depends on validated performance across diverse populations, transparent regulatory clearance, cybersecurity controls, interoperability, and clinician trust in outputs that augment rather than replace expert decision-making.

Key Regional Insights

Asia-Pacific is one of the most dynamic regions for gastrointestinal endoscopy devices as China, Japan, India, South Korea, Australia, and ASEAN markets invest in cancer screening, tertiary care expansion, and medical technology localization. Japan remains a leader in endoscopic innovation, early gastric cancer detection, and advanced procedural expertise, while China and India present large-scale demand linked to population size, rising gastrointestinal disease awareness, urban hospital expansion, and broader access to minimally invasive care. South Korea and Australia add strong screening infrastructure and digital health adoption, supporting demand for premium visualization, endoscopic ultrasound, and AI-ready platforms.

North America benefits from established reimbursement, guideline-backed colorectal cancer screening, and a dense installed base of hospitals and ambulatory endoscopy centers. Europe is shaped by national screening programs, EU Medical Device Regulation requirements, clinical evidence expectations, and strong public procurement discipline. Latin America, led by Brazil and Mexico, is advancing through private hospital networks, public cancer control initiatives, and growing specialist capacity. The Middle East, particularly GCC countries, is investing in advanced hospitals, specialty care, and medical tourism infrastructure, while Africa remains underpenetrated but offers long-term opportunity as diagnostic capacity, referral pathways, and workforce training improve.

Key Group Insights

ASEAN demand is rising as Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and Singapore expand specialist care, private hospital capacity, and cancer awareness programs, although affordability, reimbursement variability, and trained endoscopist availability remain uneven. GCC countries are prioritizing advanced hospitals, medical tourism, noncommunicable disease programs, and high-acuity specialty services, creating opportunities for premium visualization systems, endoscopic ultrasound, infection prevention solutions, and service-led procurement models.

The European Union is defined by harmonized regulatory oversight, value-based purchasing, national colorectal screening frameworks, and post-market surveillance expectations under strengthened medical device rules. BRICS markets combine large patient populations with domestic manufacturing ambitions, localization pressure, mixed reimbursement maturity, and expanding tertiary care access, requiring adaptable product portfolios and region-specific pricing models. G7 countries represent high-value innovation markets with strong clinical evidence expectations, advanced digital infrastructure, and rapid evaluation of AI-enabled endoscopy. NATO countries overlap significantly with mature Western health systems, where supply resilience, cybersecurity, procurement transparency, and critical medical technology availability increasingly shape device selection.

Key Country Insights

The United States leads adoption of gastrointestinal endoscopy devices through guideline-backed colorectal cancer screening, ambulatory endoscopy center growth, established reimbursement, and early uptake of AI-enabled imaging and documentation tools. Canada emphasizes equitable screening access and quality improvement across provincial health systems, while Mexico and Brazil show expanding private-sector demand alongside public initiatives for cancer diagnosis and specialty care. In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from national screening frameworks, advanced clinical centers, and strong adoption of high-definition imaging and therapeutic endoscopy; Russia presents demand for essential endoscopy access but faces procurement, supply, and geopolitical constraints.

China is scaling domestic production, tertiary hospital capacity, and digestive disease diagnostics, supported by hospital modernization and rising awareness of colorectal and upper gastrointestinal cancers. India is expanding procedure access through urban hospital networks, specialist training, and private healthcare investment, though affordability and geographic access remain key constraints. Japan remains central to endoscopic technology development, early cancer detection practices, and advanced therapeutic procedures. Australia maintains strong screening infrastructure and quality-driven care pathways, while South Korea combines high screening participation, advanced hospitals, rapid digital health adoption, and strong procedural expertise, supporting demand for premium gastrointestinal endoscopy devices and software-enabled systems.

Actionable Recommendations for Industry Leaders

Industry leaders should align portfolios with the full endoscopy workflow rather than isolated devices. High-value strategies include AI-ready imaging platforms, validated infection prevention solutions, durable and single-use options where clinically justified, and accessories that support therapeutic procedures such as hemostasis, endoscopic resection, drainage, dilation, and stenting.

Commercial execution should focus on clinical evidence generation, physician training, total cost of ownership, interoperability, and region-specific reimbursement pathways. Manufacturers should strengthen supply chain redundancy, regulatory surveillance, cybersecurity compliance, product traceability, and post-market performance monitoring. Partnerships with hospitals, academic centers, ambulatory networks, and local distributors can accelerate adoption while supporting safe, standardized, and efficient gastrointestinal endoscopy procedure delivery.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on validated healthcare, regulatory, and clinical sources. Inputs include public guidance from organizations such as the World Health Organization, International Agency for Research on Cancer, U.S. Preventive Services Task Force, U.S. Food and Drug Administration, European Commission, and national cancer screening authorities.

The analysis synthesizes disease burden, screening recommendations, technology adoption, regulatory trends, care delivery models, procurement dynamics, and device safety considerations. Insights are cross-checked against peer-reviewed clinical literature, regulatory clearances, public health system publications, and recognized medical society guidance to ensure that conclusions remain evidence-based, market-relevant, and suitable for executive decision-making.

Conclusion

The gastrointestinal endoscopy devices market is entering a more technology-intensive phase shaped by colorectal cancer screening, minimally invasive therapy, AI-enabled visualization, infection prevention, and heightened quality expectations. Device makers that combine clinical utility with workflow integration, compliance, interoperability, and training will be best positioned to address sustained procedural demand.

Regional differences remain significant, but the direction of travel is consistent: earlier detection, safer procedures, better documentation, improved therapeutic capability, and expanded access to endoscopy services. Organizations that build credible clinical evidence, localize commercial models, strengthen supply resilience, and integrate AI responsibly can enhance competitiveness in both mature and emerging healthcare systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastrointestinal Endoscopy Devices Market, by Product Type

• 7.1. Endoscopes
  • 7.1.1. Gastroscopes
  • 7.1.2. Colonoscopes
  • 7.1.3. Duodenoscopes
  • 7.1.4. Enteroscopes
• 7.2. Operative Devices
  • 7.2.1. Forceps
  • 7.2.2. Scissors
  • 7.2.3. Snares
• 7.3. Visualization Equipment
  • 7.3.1. Cameras
  • 7.3.2. Light Sources
  • 7.3.3. Monitors
  • 7.3.4. Endoscopy Video Processors
• 7.4. Accessories
  • 7.4.1. Cameras
  • 7.4.2. Guide Wires
  • 7.4.3. Insertion Tubes

8. Gastrointestinal Endoscopy Devices Market, by Form Factor

• 8.1. Flexible Devices
• 8.2. Rigid Devices

9. Gastrointestinal Endoscopy Devices Market, by Category

• 9.1. Reusable
• 9.2. Single-Use

10. Gastrointestinal Endoscopy Devices Market, by Indication

• 10.1. GI Bleeding
• 10.2. Colorectal Cancer
• 10.3. Inflammatory Bowel Disease (IBD)
• 10.4. Polyps
• 10.5. Barrett's Esophagus
• 10.6. Pancreatic Disorders

11. Gastrointestinal Endoscopy Devices Market, by Application

• 11.1. Diagnostics
• 11.2. Therapeutics

12. Gastrointestinal Endoscopy Devices Market, by End User

• 12.1. Ambulatory Surgery Centers
• 12.2. Hospitals
• 12.3. Specialty Clinics

13. Gastrointestinal Endoscopy Devices Market, by Age Group

• 13.1. Adults
• 13.2. Geriatrics
• 13.3. Pediatrics

14. Gastrointestinal Endoscopy Devices Market, by Sales Channel

• 14.1. Direct Sales
• 14.2. Distributor Sales
• 14.3. Online Sales

15. Gastrointestinal Endoscopy Devices Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Gastrointestinal Endoscopy Devices Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Gastrointestinal Endoscopy Devices Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Ambu A/S
• 19.3. Becton, Dickinson and Company
• 19.4. Boston Scientific Corporation
• 19.5. Cardinal Health Inc.
• 19.6. ConMed Corporation
• 19.7. Cook Medical, Inc.
• 19.8. Erbe Elektromedizin GmbH
• 19.9. Fujifilm Holdings Corporation
• 19.10. Johnson & Johnson Services Inc.
• 19.11. KARL STORZ SE & Co. KG
• 19.12. Medtronic plc
• 19.13. Merit Medical Systems, Inc.
• 19.14. MICRO-TECH (Nanjing) Co., Ltd.
• 19.15. Olympus Corporation
• 19.16. Ovesco Endoscopy AG
• 19.17. PENTAX Medical America, Inc.
• 19.18. Richard Wolf GmbH
• 19.19. SB-KAWASUMI LABORATORIES, INC.
• 19.20. Shanghai Aohua Photoelectricity Endoscope Co.,Ltd.
• 19.21. Smart Medical Systems Ltd.
• 19.22. Smith & Nephew plc
• 19.23. SonoScape Medical Corp.
• 19.24. STERIS plc
• 19.25. Stryker Corporation
• 19.26. Teleflex Incorporated